You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Frequently Overlooked Complications of Liver Disease: Guide for Community Providers

  • Authors: Steven L. Flamm, MD; Amanda Chaney, DNP, APRN, FAANP; Arun Jesudian, MD
  • CME / ABIM MOC / CE Released: 5/25/2023
  • Valid for credit through: 5/25/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.75 ABIM MOC points

    Nurses - 0.75 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    IPCE - 0.75 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for gastroenterologists, primary care physicians, nurse practitioners, nurses/advanced practice nurses, and other clinicians who manage patients with hepatic encephalopathy (HE).

The goal of this activity is for learners to be better able to identify at-risk individuals and manage HE with a multidisciplinary care team in rural settings.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Complications of cirrhosis
    • Clinical manifestations of HE
  • Have greater competence related to
    • Assessment and diagnosis of HE within an interprofessional care team
    • Tailoring treatments for HE based on clinical evidence


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Steven L. Flamm, MD

    Professor of Medicine
    Rush University Medical Center
    Chicago, Illinois


    Steven L. Flamm, MD, has no relevant financial relationships.

  • Amanda Chaney, DNP, APRN, FAANP

    Senior Director of Advanced Practice Provider Services
    Cleveland Clinic
    Weston, Florida


    Amanda Chaney, DNP, APRN, FAANP, has no relevant financial relationships.

  • Arun Jesudian, MD

    Associate Professor of Clinical Medicine
    Weill Cornell Medicine
    New York, New York


    Arun Jesudian, MD, has the following relevant financial relationships:
    Consultant or advisor for: Dynavax Technologies Corporation; Salix Pharmaceuticals, Inc.
    Speaker or member of speakers bureau for: Salix Pharmaceuticals, Inc.
    Research funding from: Camurus; Salix Pharmaceuticals, Inc.


  • Karen Badal, MD, MPH

    Senior Medical Education Director, Medscape, LLC


    Karen Badal, MD, MPH, has no relevant financial relationships.

  • Jason Luis Quiñones, PhD

    Associate Medical Writer, Medscape, LLC


    Jason Luis Quiñones, PhD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

    For Nurses

  • Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Frequently Overlooked Complications of Liver Disease: Guide for Community Providers

Authors: Steven L. Flamm, MD; Amanda Chaney, DNP, APRN, FAANP; Arun Jesudian, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 5/25/2023

Valid for credit through: 5/25/2024, 11:59 PM EST



  1. Centers for Disease Control and Prevention. Chronic liver disease and cirrhosis. Updated January 17, 2023. Accessed April 26, 2023.
  2. Centers for Disease Control and Prevention. Leading causes of death. Updated January 2023. Accessed April 26, 2023.
  3. Scaglione S, et al. The epidemiology of cirrhosis in the United States. J Clin Gastroenterol. 2015;49:690-696.
  4. Loomba R, et al. AGA clinical practice update on screening for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology. 2020;158:1822-1830.
  5. Hofmeister MG, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. Hepatology. 2019;69:1020-1031.
  6. Gish RG, et al. Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States. Hepatology. 2015;62:1339-1341.
  7. Huang DQ, et al. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023;20:37-49.
  8. Chen PH, et al. Inter-hospital escalation-of-care referrals for severe alcohol-related liver disease with recent drinking during the COVID-19 pandemic. Alcohol Alcohol. 2022;57:185-189.
  9. Larson PS, et al. Impact of the COVID-19 pandemic on temporal patterns of mental health and substance abuse related mortality in Michigan: an interrupted time series analysis. Lancet Reg Health Am. 2022;10:100218.
  10. Singal AK, et al. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA. 2021;326:165-176.
  11. Ekstedt M, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865-873.
  12. Sorrentino P, et al. Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol. 2004;41:751-757.
  13. Bertot LC, et al. Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. Hepatol Commun. 2017;1:53-60.
  14. Heidelbaugh JJ, et al. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006;74:756-762.
  15. Johnston DE. Special considerations in interpreting liver function tests. Am Fam Physician. 1999;59:2223-2230.
  16. Zeman MV, et al. Autoantibodies and liver disease: uses and abuses. Can J Gastroenterol. 2010;24:225-231.
  17. Moore AH. Thrombocytopenia in cirrhosis: a review of pathophysiology and management options. Clin Liver Dis. 2019;14:183-186.
  18. Bert F, et al. Ultrasound elastography used for preventive non-invasive screening in early detection of liver fibrosis. J Clin Med Res. 2016;8:650-655.
  19. Garcia-Compean D, et al. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol. 2009;15:280-288.
  20. Vora RS, et al. Hypotension in cirrhosis. Clin Liver Dis. 2019;13:149-153.
  21. Naga C, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Disease. Hepatology. 2018;67:328-357.
  22. Nielsen AS, et al. Treatment of alcohol use disorder in patients with liver disease. Curr Opin Pharmacol. 2022;62:145-151.
  23. Thomas DL, et al. Detection of liver disease in injection drug users. J Addict Dis. 2008;27:19-24.
  24. Alberts C, et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol. 2022;7:724-735.
  25. Marrero JA, et al. Diagnosing, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723-750.
  26. European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406-460.
  27. Omata M, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370.
  28. Di Martino V, et al. New prognostic markers in liver cirrhosis. World J Hepatol. 2015;7:1244-1250.
  29. Ginés P, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7:122-128.
  30. D'Amico G, et al. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217-231.
  31. D'Amico G, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39:1180-1193.
  32. Shetty A, et al. The gastroenterologist's guide to preventive management of compensated cirrhosis. Gastroenterol Hepatol. 2019;15:423-430.
  33. Vilstrup H, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Disease and the European Association for the Study of the Liver. Hepatology. 2014;60:715-735.
  34. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatic encephalopathy. 2022;77:807-824.
  35. Child CG, et al. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1-85.
  36. Pugh RN, et al. Transection of the esophagus for bleeding esophageal varices. Br J Surg. 1973;60:646-649.
  37. Ufere N, et al. Rural-urban disparities in mortality from cirrhosis in the United States from 1999 to 2019. Am J Gastroenterol. 2022;1162-1165.
  38. Kardashian A, et al. Health disparities in chronic liver disease. Hepatology. 2023;77:1382-1403.
  39. US Food and Drug Administration. Rural health. Updated June 22, 2021. Accessed April 26, 2023.
  40. Rongey C, et al. Impact of rural residence and health system structure on quality of liver care. PLoS One. 2013;8:e84826.
  41. Chartampilas E, et al. Imaging of nonalcoholic fatty liver disease and its clinical utility. Hormones. 2018;17:69-81.
  42. Reschovsky JD, et al. Access and quality: does rural America lag behind? Health Aff (Millwood). 2005;24:1128-1139.
  43. Mellinger JL, et al. Multidisciplinary management of patients with cirrhosis: a need for care coordination. Clin Gastroenterol Hepatol. 2013;11:217-223.
  44. Mukthinuthalapati VVPK, et al. Early predictors of outcomes of hospitalization for cirrhosis and assessment of the impact of race and ethnicity at safety-net hospitals. PLoS One. 2019;14:e0211811.
  45. Perez IC, et al. Step by step: managing the complications of cirrhosis. Hepat Med. 2021;13:45-57.
  46. Flamm SL. Complications of cirrhosis in primary care: recognition and management of hepatic encephalopathy. Am J Med Sci. 2018;356:296-303.
  47. Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014;18:281-291.
  48. Bustamente J, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30:890-895.
  49. Kabaria S, et al. Hepatic encephalopathy: a review. EMJ Hepatol. 2021;9:89-97.
  50. Elsaid MI, et al. Epidemiology of hepatic encephalopathy. Clin Liver Dis. 2020;24:157-174.
  51. López-Franco Ó, et al. Cognitive impairment after resolution of hepatic encephalopathy: a systematic review and meta-analysis. Front Neurosci. 2021;15:579263.
  52. Moore KP, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55(Suppl 6):vi1-vi12.
  53. Philips CA, et al. Updated on diagnosis and management of sepsis in cirrhosis: current advances. World J Hepatol. 2020;12:451-474.
  54. Djiambou-Nganjeu H. Hepatic encephalopathy in liver cirrhosis. J Transl Int Med. 2017;5:64-67.
  55. Cordoba J, et al. New assessment of hepatic encephalopathy. J Hepatol. 2011;54:1030-1040.
  56. Bernal W, et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology. 2007;46:1844-1852.
  57. Clemmesen JO, et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology. 1999;29:648-653.
  58. Ong JP, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2003;114:188-193.
  59. Centers for Disease Control and Prevention. About rural health. Updated August 2, 2017. Accessed April 25, 2023.
  60. Liu A, et al. Hepatic encephalopathy: what the multidisciplinary team can do. J Multidiscip Healthc. 2017;10:113-119.
  61. Deng LX, et al. Thinking ahead: advanced care planning for patients with cirrhosis. Clin Liver Dis. 2022;19:7-11.
  62. Goldberg DS, et al. Association of distance from a transplant center with access to waitlist placement, receipt of liver transplantation, and survival among US veterans. JAMA. 2014;311:1234-1234.
  63. Ufere NN, et al. Financial burden in adults with chronic liver disease: a scoping review. Liver Transpl. 2022;28:1920-1935.
  64. Neff G, et al. Systematic review of the economic burden of overt hepatic encephalopathy and pharmacoeconomic impact of rifaximin. Pharmacoeconomics. 2018;36:809-822.
  65. Bass NM, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071-1081.
  66. Flamm SL. Considerations for the cost-effective management of hepatic encephalopathy. Am J Manag Care. 2018;24(Suppl):S51-S61.
  67. Stoll AM, et al. Lack of access to rifaximin upon hospital discharge is frequent and results in increased hospitalizations for hepatic encephalopathy. Ann Pharmacother. 2022;57:133-140.
  68. Noor MT, et al. Immune dysfunction in cirrhosis. J Clin Transl Hepatol. 2017;5:50-58.
  69. Bajaj JS, et al. The evolving challenge of infections in cirrhosis. N Engl J Med. 2021;384:2317-2330.
  70. Stravitz RT. Management of the cirrhotic patient before liver transplantation: the role of the referring gastroenterologist. Gastroenterol Hepatol. 2006;2:346-354.
  71. Fallahzadeh MA, et al. Hepatic encephalopathy: current and emerging treatment modalities. 2022;20:S9-S19.
  72. Hoilat GJ, et al. Evidence-based approach to management of hepatic encephalopathy in adults. World J Hepatol. 2022;14:670-681.
  73. A 6-month efficacy, safety, and tolerability study of rifaximin in preventing hepatic encephalopathy. Accessed April 27, 2023.
  74. Rifaximin [prescribing information]. Approved 2004. Revised October 2022.
  75. Shibolet O, et al. Air transportation of patients with end-stage liver disease to distant liver transplantation centers. Liver Transpl. 2005;11:650-655.
  76. Hayward KL, et al. Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis. World J Gastroenterol. 2017;23:7321-7331.
  77. Hudson M, et al. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol. 2019;31:434-450.
  78. Biggins SW, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Disease. Hepatology. 2021;74:1014-1048.
  79. Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Disease practice guidelines management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57:1651-1653.
  80. Jones LK, et al. Understanding the medication prior-authorization process: a case study of patients and clinical staff from a large rural integrated health delivery system. Am J Health Syst Pharm. 2019;76:453-459.
  81. Stotts MJ, et al. Improving cirrhosis care: the potential for telemedicine and mobile health technologies. World J Gastroenterol. 2019;25:3849-3856.
  82. Ganapathy D, et al. The patient buddy app can potentially prevent hepatic encephalopathy-related readmissions. Liver Int. 2017;37:1843-1851.
  83. Frenette CT, et al. Hepatic encephalopathy-related hospitalizations in cirrhosis: transition of care and closing the revolving door. Dig Dis Sci. 2022;67:1994-2004.
  84. Rogal SS, et al. AASLD practice guidance: palliative care and symptom-based management in decompensated cirrhosis. Hepatology. 2022;76:819-853.
« Return to: Frequently Overlooked Complications of Liver Disease: Guide for Community Providers
  • Print